ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 166

The Potential Role Of Protein Tyrosine Phosphatase Receptor D (PTPRD) Gene Copy Number Variation In Susceptibility To Rheumatoid Arthritis

Su Jin Yoo1, Mi Kyoung Lim2, Donghyuk Sheen3, In Seol Yoo4, Jinhyun Kim5, Seong Wook Kang4 and Seung-Cheol Shim6, 1Rheumatology, Chungnam National University School of Medicine, Daejeon, South Korea, 2Medicine, Eulji University Hospital, Daejeon, South Korea, 3Rheumatology, Eulji University Hospital, Daejeon, South Korea, 4Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, 5Internal medicine, Chungnam National University School of Medicine, Daejeon, South Korea, 6Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Genetics and Genomics of Rheumatic Disease I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Since it is important to explore genetic variations associated with rheumatoid arthritis (RA), genome-wide association studies (GWAS) have led to the identification of RA genetic variants putatively associated with susceptibility. Recently, copy number variation (CNV) may also affect susceptibility to diseases, which have been already observed in diverse autoimmune diseases. Protein tyrosine phosphatase receptor D (PTPRD) is a member of the receptor-like PTP which expresses in the B cell lines and thymus and could be involved in the pathogenesis of autoimmune diseases. In this study, we investigated whether the variation of the PTPRD gene copy number related with susceptibility to RA.

Methods: To investigate whether the variation of the PTPRD gene copy number influence the pathogenesis to RA, blood samples and clinical records were obtained from 217 RA patients (184 females, 33 males) and 205 healthy controls. The genomic DNA of RA patients and healthy controls was extracted from leukocytes in peripheral blood using the Genomic DNA Extraction kit (iNtRON Biotechnology, Korea). To measuring the copy number of PTPRD gene, the quantitative real-time PCR (QPCR) was carried out using Mx3000P QPCR system (Stratagene, La Jolla, CA) and each sample for each gene was assayed in triplicate. Western blot was conducted to detect expression levels of PTPRD

Results: The copy number of PTPRD gene in RA patients was compared with that in healthy controls. The proportion of the individuals with <2 copy of VPREB1 was significantly higher in patients than in controls, while that of the individuals with >2 copy was lower in patients than in controls. The average relative copy number of the PTPRD gene in RA patients (1.14, 95 % CI (1.12-1.16)) was significantly lower than that in healthy controls (1.65, 95 % CI (1.12-1.16), p < 0.0001). Furthermore, we also investigated association between copy number of PTPRD and RA phenotype such as RF factor and anti-CCP levels, which showed no association between copy number of PTPRD and both RA phenotypes. Western blot showed the lower expression of PTPRD in patients with RA compared to control subjects .

Conclusion: This is the first evidence showing the association between low copy number of the PTPRD gene and susceptibility to RA, which may help understanding the pathogenesis of RA and other autoimmune disorders like affecting maturation and differentiation of T cell and B cells.


Disclosure:

S. J. Yoo,
None;

M. K. Lim,
None;

D. Sheen,
None;

I. S. Yoo,
None;

J. Kim,
None;

S. W. Kang,
None;

S. C. Shim,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-potential-role-of-protein-tyrosine-phosphatase-receptor-d-ptprd-gene-copy-number-variation-in-susceptibility-to-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology